AbbVie receives US antitrust approval for planned Pharmacyclics buyout
( May 22, 2015, 13:45 GMT | Official Statement) -- MLex Summary: AbbVie said Friday that the company has received US antitrust approval for its planned $21 billion acquisition of cancer drugmaker Pharmacyclics. The antitrust waiting period under the Hart-Scott-Rodino Act expired without a request for more information from regulators, the company said.Statement follows in full....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.